Baudax Bio (BXRX) Misses Q2 EPS by $1.07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Baudax Bio Reports Second Quarter 2020 Financial Results
August 10, 2020 7:15 AM EDTCommenced Commercial Launch of ANJESO® in the U.S.
Awarded J-Code from CMS
Executed Contract with a top National GPO for hospital purchases, Vizient, and one of the top 3 IDNs Nationally
Secured $50 Million Credit Facility
MALVERN, Pa., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today reported financial results for the three and six months ended June 30, 2020.
... More